Top

Dermatology and Therapy

Published in:

Open Access 01-12-2014 | Review

Ingenol Mebutate: A Succinct Review of a Succinct Therapy

Author: David Rhys Alchin

Published in: Dermatology and Therapy | Issue 2/2014

Abstract

Background

Ingenol mebutate is a newly approved topical field therapy for actinic keratosis (AK). It has a dual mechanism of action comprising of a rapid induction of necrosis that specifically targets dysplastic cells, as well as neutrophil-mediated immunostimulatory effects. Such a dual mechanism allows for this agent to clear AK lesions in as little as two to three daily applications, thus providing for improved treatment outcomes and patient satisfaction.

Review

Given that this is a new dermatologic therapy, this review summarizes the key literature surrounding this agent. This review covers the indications for use, mechanisms of action, method of administration, efficacy and safety profile and important drug interactions of ingenol mebutate.

Conclusions

Ingenol mebutate should be considered a highly relevant field therapy for AK and the prevention of progression to squamous cell carcinoma.

Available only for authorised users

Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol. 2013;68(1 Suppl 1):S10–9.PubMedCrossRef

Sotiriou E, Apalla Z, Vrani F, Lallas A, Chovarda E, Ioannides D. Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes: a randomized intra individual comparison study. JEADV. 2014.

Chia A, Lim A, Shumack S, Moreno G. Actinic keratoses. Aust Fam Phys. 2007;36(7):539.

Goldenberg G. Optimal treatment of actinic keratosis. Clin Interv Aging. 2014;9:15–6.PubMedCentralPubMed

Perl M, Goldenberg G. Field therapy in the treatment of actinic keratosis. Cutis. 2014;93(4):172–3.PubMed

Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. Dermatol Ther (Heidelb). 2014;4(1):11–31.CrossRef

Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149(6):666–70.

Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51(2):99–105.PubMedCrossRef

Gupta AK, Paquet M. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers. J Cutan Med Surg. 2013;17(3):173–9.PubMed

10.

Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60(6):934–43.PubMedCrossRef

11.

Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66(3):486–93.PubMedCrossRef

12.

Samrao A, Cockerell CJ. Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents. Am J Clin Dermatol. 2013;14(4):273–7.PubMedCrossRef

13.

Fidler B, Goldberg T. Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses. Pharm Ther. 2014;39(1):40–6.

14.

Stahlhut M, Bertelsen M, Hoyer-Hansen M, Svendsen N, Eriksson AH, Lord JM, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. JDD. 2012;11(10):1181–92.PubMed

15.

Ersvaer E, Kittang AO, Hampson P, Sand K, Gjertsen BT, Lord JM, et al. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity. Toxins. 2010;2(1):174–94.PubMedCentralPubMedCrossRef

16.

Fallen RS, Gooderham M. Ingenol mebutate: an introduction. Skin Ther Lett. 2012;17(2):1–3.

17.

Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16–22.PubMedCrossRef

18.

Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. New Engl J Med. 2012;366(11):1010–9.PubMedCrossRef

19.

Dosik JS, Damstra M, Udell C, Welburn P. Evaluation of the skin sensitization, photo irritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers. J Clin Aesthet Dermatol. 2014;7(4):35–42.PubMedCentralPubMed

20.

Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol. 2013;68(1 Suppl 1):S39–48.PubMedCrossRef

Title: Ingenol Mebutate: A Succinct Review of a Succinct Therapy
Author: David Rhys Alchin
Publication date: 01-12-2014
Publisher: Springer Healthcare
Published in: Dermatology and Therapy / Issue 2/2014
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-014-0061-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Ingenol Mebutate: A Succinct Review of a Succinct Therapy

Abstract

Background

Review

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Review

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2014

Methotrexate Toxicity During Treatment of Chronic Plaque Psoriasis: A Case Report and Review of the Literature

The Efficacy of Combined Herbal Extracts Gel Preparation in the Prevention of Postsurgical Hypertrophic Scar Formation

A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate

Correction of Skin Contour Defects in Leaking Stomas by Filler Injection: A Novel Approach for a Difficult Clinical Problem

Efficacy and Safety of Nadifloxacin for Bacterial Skin Infections: Results from Clinical and Post-Marketing Studies

Topical, Non-Medicated LOYON® in Facilitating the Removal of Scaling in Infants and Children with Cradle Cap: a Proof-of-Concept Pilot Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page